A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Anagrelide
- Indications Thrombocytosis
- Focus Registrational; Therapeutic Use
- Acronyms RESET-272
- Sponsors Incyte Corporation
- 15 Nov 2017 According to an Incyte Corporation media release, first patient has been dosed.
- 06 Jun 2017 Status changed from not yet recruiting to recruiting.
- 24 Apr 2017 New trial record